Matsumoto Masahiro
   Department   School of Medicine  Urology, Clinical Medical Sciences
   Position  
Article types 不明
Language English
Peer review Non peer reviewed
Title Clinical effectiveness and safety of tazobactam/piperacillin 4.5 g for the prevention of febrile infectious complication after prostate biopsy.
Journal Formal name:Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy
Abbreviation:J Infect Chemother
ISSN code:14377780/1341321X
Domestic / ForeginForegin
Volume, Issue, Page 20(10),631-4頁
Author and coauthor Yasuda Mitsuru, Nakane Keita, Yamada Yoshiteru, Matsumoto Masahiro, Sho Takehiko, Matsumoto Minori, Kobayashi Kanao, Shigemura Katsumi, Nakano Yuzo, Tanaka Kazushi, Hamasuna Ryoichi, Ishihara Satoshi, Arakawa Soichi, Yamamoto Shingo, Matsubara Akio, Fujisawa Masato, Deguchi Takashi, Matsumoto Tetsuro
Publication date 2014/10
Summary We investigated the clinical effectiveness and safety of tazobactam/piperacillin (TAZ/PIPC) in a 1:8 ratio, a β-lactamase inhibitor with penicillin antibiotic, for the prevention of febrile infectious complication after prostate biopsy. Each patient received a single dose of TAZ/PIPC 4.5 g, 30 min before the biopsy in Group 1 or TAZ/PIPC 4.5 g twice, once 30 min before and once after the biopsy (just before discharge or 5 h after the biopsy), in Group 2. Estimation of efficacy was performed within 1-month after prostate biopsy. Clinical diagnosis of febrile infectious complication was based on a body temperature elevation greater than 38 °C. Infectious complication after prostate biopsy was detected in 2.5% (4/160 patients) in Group 1 and in 0.45% (2/442 patients) in Group 2. All of the patients with febrile infectious complication had risk factors: 5 patients had voiding disturbance, 2 patients had diabetes mellitus and 1 patient had steroid dosing. In group 1, 88 patients had at least one risk factor and 72 patients had no risk factors. Of the patients with a risk factor, 4 had febrile infectious complication after prostate biopsy, but there was no significant difference between the two groups. In group 2, 87 patients had at least one risk factor and 255 patients had no risk factors. The patients with a risk factor had febrile infectious complication significantly more frequently than did patients without a risk factor (P = 0.038). Therefore, TAZ/PIPC appears to be effective as preoperative prophylaxis against the occurrence of febrile infectious complication after prostate biopsy.
DOI 10.1016/j.jiac.2014.06.011
PMID 25043444